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KAJIAN PENEROKAAN TERHADAP PENYAKIT PEMBULUH DARAH 
KECIL BAGI INDIVIDU ASIMPTOMATIK MELALUI PROFIL 
NEUROPSIKOLOGI, NEUROPENGIMEJAN, DAN MIKROPARTIKEL. 
 
ABSTRAK  
 
Secara lazimnya penyakit pembuluh darah kecil otak (CSVD) yang kelihatan 
asimptomatik ('senyap') dilihat sebagai hiperintensiti jirim putih (WMHs) pada 
Pengimejan Resonans Magnetik (MRI). Kajian ini bertujuan untuk meninjau penanda 
pengganti baru untuk penilaian integriti jirim putih dalam CSVD di kalangan individu 
yang tidak bersimptom melalui profil neuropsikologi, neuropengimejan dan 
micropartikel (MPs). Subjek yang direkrut dengan skor ramalan risiko kardiovaskular 
yang rendah kepada sederhana seperti yang ditakrifkan oleh QRISK2 menjalani 
imbasan otak MRI, diikuti oleh penilaian neuropsikologi yang mengukur daya 
pemikiran persepsi (PRI), memori kerja (WMI) dan kelajuan pemprosesan (PSI) 
menggunakan Weschler Adults Intelligence Scale (WAIS -IV). Sebelum ujian ‘flow 
cytometry’ untuk mengira kadar MPs, 18 ml darah (puasa) telah diambil. Prosedur 
yang sama dijalankan selepas 12 bulan. Pada peringkat awal, 48 orang yang 
asimptomatik telah direkrut (purata umur: 38.81 ± 10.9); 24 orang dewasa muda, YA 
(purata umur 29.7 ± 4.33) dan 24 orang dewasa tua, MA (purata umur: 47.92 ± 7.01). 
Lima belas (29.4%) subjek mempunyai WMHs (WMH+) telah dikesan, lima 
daripdanya adalah YA, dan 10 adalah MA. Walau bagaimanapun, selepas 12 bulan, 
hanya 40 (purata umur: 39.35 ± 11.31) dapat menyertai; lapan (20%) subjek tidak 
kembali menyertai kajian, empat belas (35%) daripada subjek adalah WMH+ dan 26 
xxx 
 
(65%) adalah WMH-. Umur mempengaruhi kehadiran WMHs, dimana subjek WMH+ 
mempunyai risiko CSVD yang lebih tinggi. WMH+ subjek menunjukkan purata 
peratusan QRISK2 dan MPs yang lebih tinggi terutamanya MPs platlet (CD41a dan 
CD62P). Dari segi integriti jirim putih, skor QRISK2 meningkat apabila integriti 
berkurang (berdasarkan anisotropi fraksional, FA), terutamanya jirim putih seperti 
superior corona radiata (SCR) dan superior longitudinal fasciculus (SLF). Integrity 
jirim putih juga berkurang dengan peningkatan umur. Prestasi PRI dan WMI berbeza 
antara subjek, tetapi PSI secara konsisten lebih rendah dalam kalangan subjek WMH+. 
Tidak ada perubahan temporal yang signifikan terhadap prestasi kognitif dan memori 
dari kedua-dua kumpulan. FA untuk kesemua jirim putih berkolerasi secara positif 
dengan profil neuropsikologi. Integriti jirim putih seperti SLF kiri dan ACR kiri adalah 
berkolerasi dengan MPs darah merah (CD235a) (r= -0.313, p=0.030) dan MPs platlet 
CD62P (r=0.289, p= 0.047). Kesimpulannya, walaupun dengan saiz sampel yang 
terhad dan tempoh susulan yang singkat, kajian ini telah membuktikan hubungan 
antara ramalan risiko kardio-serebrovaskular oleh QRISK2, prestasi indeks 
neuropsikologi, integriti jirim putih/WMHs dari MRI dan profil MPs sebagai penanda 
yang berpotensi untuk CSVD dalam individu-individu yang sihat dan asimtomatik. 
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EXPLORATORY LONGITUDINAL STUDIES ON CEREBRAL SMALL 
VESSEL DISEASE (CSVD) IN APPARENTLY ASYMPTOMATIC 
INDIVIDUALS WITH NEUROPSYCHOLOGICAL, NEUROIMAGING AND 
MICROPARTICLES PROFILING 
 
ABSTRACT 
 
The prevalence of cerebral small vessel disease (CSVD) for asymptomatic (‘silent’) 
manifestation is typically obtained from incidental findings of white matter 
hyperintensities (WMHs) on magnetic resonance imaging (MRI). This study aimed to 
explore novel surrogate markers for the assessment of white matter integrity in CSVD 
among apparently asymptomatic individuals with neuropsychological, neuroimaging 
and microparticles (MPs) profiling. The recruited subjects with low to moderate 
cardiovascular risk prediction score as defined by QRISK2 underwent MRI brain scan, 
followed by neuropsychological indices of Weschler Adults Intelligence Scale 
(WAIS-IV) that measured their perceptual reasoning (PRI), working memory (WMI) 
and processing speed (PSI). Prior to flow cytometry MPs subpopulations 
enumerations, 18 ml of fasting blood was collected. Similar procedures were carried 
out at baseline (T0) and at 12 months follow-up (T12). At baseline, 48 asymptomatic 
individuals were recruited (mean age: 38.81±10.9); 24 were young adults, YA (mean 
age 29.7±4.33) and 24 mature adults, MA (mean age: 47.92±7.01). Fifteen (29.4%) 
had WMHs (WMH+) detected, of who five were YA, and 10 were MA. However, after 
one-year, 40 (mean age: 39.35±11.31) were able to participate; eight (20%) subjects 
were lost to follow up fourteen (35%) subjects were WMH+ and 26 (65%) were WMH-
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. Age influenced the presence of WMHs and WMH+ subject as having higher risk of 
CSVD. WMH+ subjects showed higher mean percentage of QRISK2 and MPs 
especially platelet derived MPs (CD41a and CD62P). In term of white matter integrity, 
QRISK2 score increased with reduced integrity (measured by fractional anisotropy, 
FA) of white matter tracts of superior corona radiata (SCR) and superior longitudinal 
fasciculus (SLF). White matter integrity was also reduced with advancing age. The 
PRI and WMI performance varied between subjects, but PSI consistently lower in 
WMH+ subjects. There were no significant temporal changes on cognitive and 
memories performances from both groups. FA of all tracts consistently and positively 
correlated with neuropsychological profiles. The integrity of white matter tracts such 
as left SLF and left anterior corona radiata were correlated with red blood cell MPs 
(CD235a) (r= -0.313, p=0.030) and CD62P (r=0.289, p= 0.047), respectively. 
Although with a relatively small sample size and one-year follow-up period, this study 
had established the correlations between cardio-cerebrovascular risk prediction by 
QRISK, neuropsychological indices performance, WMHs/white matter integrity from 
diffusion MRI and MPs profiling as potential surrogate markers for CSVD in 
apparently asymptomatic individuals. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background of The Study 
 
Cerebral small vessel disease (CSVD) is a spectrum of histopathological, clinical and 
imaging abnormalities linked to the pathology of microvasculature of small 
penetrating arteries and arterioles in brain irrigating subcortical structures (Lammie, 
2005; Pantoni, 2010). In general, it results in a brain parenchyma injury invariably 
associated with distal leptomeningeal and intracerebral vessel pathology that affects 
deep cerebral white matter integrity (Ogata et al., 2014). CSVD is characterised by 
arteriosclerosis and/or micro-atheromatosis of cerebral arteries of small calibre (50-
500 µm) caused by various pathologies (Lammie, 2005). Current data suggest that 
CSVD is one of the most prevalent neurological disorders in the ageing society of the 
developed world (Hachinski, 2008; Thompson & Hakim, 2009). The prevalence of 
CSVD’s seemingly asymptomatic manifestation such as silent brain infarcts (SBI) or  
white matter hyperintensities (WMHs) is recognised to be higher with advancing age 
(Gunda et al., 2012).  
 
Generally, the microvasculature health of the small vessels is maintained by 
normal functioning endothelial cells that lines the vessel wall. However, the formation 
of microparticles (MPs) have been reported to contribute to the disorganisation of the 
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proper function of endothelium layers. For example, Martinez et al., 2011, have shown 
that endothelial dysfunction caused by MPs can induce vascular inflammation that 
potentially leads to a prothrombotic state in arteriolo- and atherosclerosis. Besides, the 
dysfunction is also demonstrated by the shedding of endothelial MPs that express 
platelet-endothelial cell adhesion molecule-1 (i.e. CD31) that has been implicated to 
feature in ischaemic stroke subtypes (Grammas et al., 2011). Aside from endothelial 
dysfunction, Schreiber et al., 2013, argued about another common pathomechanism of 
CSVD which is related to the disorganisations of the arterial segmental walls and 
luminal narrowing. These arose due to accumulations of MPs alongside with 
cholesterol crystals that caused arteriolosclerosis which may result in hypoperfusion 
that accompanied infarcts and WMHs (Ogata et al., 2011; Schreiber et al., 2013). 
 
The ischaemic consequences of several manifestation of CSVD such as 
WMHs, lacunar strokes, cerebral microbleeds, enlarged perivascular spaces, and small 
subcortical infarcts can be detected using magnetic resonance imaging (MRI) 
(Lambert et al., 2015; Sorond et al., 2015; Yakushiji et al., 2016; Yakushiji et al., 
2018). WMHs are commonly recognized as small ‘lacunes’ (Latin: for lake) in ageing 
brain or bright areas of small non-cavitated high signal intensities on fluid attenuated 
inversion recovery (FLAIR) and T2-weighted MRI sequences. The lesion will increase 
with age because they evolve over a few months to years (Ovbiagele & Saver, 2006; 
Valdés Hernández et al., 2015; Wharton et al., 2015). 
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Although the association between age and WMHs prevalence has been 
consistently shown across different studies, the correlation of WMHs with other 
cardiovascular risk factors and clinical proforma remain elusive. Since WMHs is 
common even in healthy individuals, risk prediction assessment would be beneficial. 
In addition to as well as a part of the risk assessment, essential clinical algorithms have 
become useful in the prevention and management of cardiovascular disease (CVD), 
including cerebrovascular events (Kanjilal et al., 2008). Thus, a tool such as QRISK2 
has been developed to assess the cardiovascular risk including cerebrovascular disease 
such as CSVD. QRISK2 is an online based risk prediction of cardio-cerebrovascular 
disease (Collins & Altman, 2012). 
 
Moreover, in healthy individuals, executive dysfunction seems to correspond 
with WMHs (O’Brien et al., 2002). The overall severity of WMHs is known to link 
with the reduction in speed of information processing and executive performance in 
patients with subcortical ischemic vascular dementia (Mungas et al., 2001). In 
contrast, such global cognitive deficits are not seen in those with additional 
heterogenous vascular dementia (Cohen et al. 2002). Also, a significant relationship 
between WMHs severity and processing speed in older adults (65-80 years of age) has 
been reported (Nebes et al., 2006). Multiple assessments tools have been developed to 
assess changes in cognitive performance in diseases and healthy individuals. To date, 
the Weschler Adults Intelligence Scale (WAIS) is the most widely used and enables 
assessing cognitive and memories function in terms of the perceptual reasoning index 
(PRI), the processing speed index (PSI) and also the working memory index (WMI) 
(Weschler et al., 2008).  
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To date, WMHs are characterised and rated in terms of volume, location, size 
and number of lesions. Hence, various visual rating scales have been developed in 
order to assess WMHs, including the Fazekas scale (Fazekas et al., 1987), which 
provides an overall impression of WMHs presence in the entire brain. Apart from that, 
the current advancement in neuroimaging technology has enabled various specific 
algorithmic techniques and tools to be developed which automatically detect the 
presence of WMHs in terms of number, volume and location. Such tools include lesion 
segmentation tool (LST) which provide more concise delineation of WMHs (Schmidt 
et al., 2012).  
 
Finally, although the conventional MRI or even MRI based diffusion-weighted 
imaging (DWI) offers detailed insights about brain anatomy and pathology, it still 
remains limited in mapping cerebral white matter, (Wang & Melhem, 2008) and more 
importantly, in correlating clinical parameters including cognition that has often been 
only weak to moderate (Patel & Markus, 2011). Therefore, better correlations and 
reliable lesion surrogates are necessary to improve the assessment of  white matter 
architecture and also connectivity, such as white matter tractography using diffusion 
based magnetic resonance imaging (dMRI)  (Lee et al., 2015; Nitkunan et al., 2008). 
Diffusion tensor imaging (DTI) is a specific signal modelling technique under 
diffusion MRI (dMRI). DTI analyses provides important information regarding white 
matter integrity and health in terms of diffusion indices. Such indices include fractional 
anisotropy (FA), mean diffusivity (MD), radial and axial diffusivity (RD and AD). 
Changes in these parameters give an insight regarding the characteristics of specific 
white matter tracts in relation to certain abnormalities including WMHs.  
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1.2 Problem Statement and Study Rationale 
 
‘Silent’ or ‘asymptomatic’ manifestation of CSVD is frequently detected an as 
incidental finding from brain imaging and is often used as a prognostic marker 
following a first symptomatic CSVD presentation (van Norden et al., 2011). On MRI, 
the microchanges in white matter are seen as WMHs that represent discrete lacunar 
infarcts and/or more diffuse areas of white matter lesion (Smith, 2010). Such changes 
as seen on a conventional MRI are of limited correlations with clinical parameters 
including cognition, ranging from weak to moderate (Patel & Markus, 2011). 
Therefore, more concise correlations and reliable lesion surrogates are needed to 
improve the assessment of white matter structure, including white matter tractography. 
Advancement in MRI techniques offer potential new information on disease 
pathomechanisms as well as surrogate markers of disease onset, progression and new 
therapy evaluations using newer MR-DTI modalities. The use of DTI offers better 
insight into white matter integrity in healthy and asymptomatic individuals, hence can 
serve as a plausible indicator of CSVD onset and progression, and to correlate with the 
manifestation of CSVD that would otherwise elude conventional MRI (Huynh et al., 
2008; Rost et al., 2010). 
 
In addition, and as part of the risk assessment, essential clinical algorithms have 
become useful in the prevention and management of CVD, including cerebrovascular 
events (Kanjilal et al., 2008). Hence, a tool such as QRISK2 has been developed to 
assess the cardiovascular risk as well as cerebrovascular disease such as CSVD. 
QRISK2 is an online based risk prediction of cardio-cerebrovascular disease (Collins 
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& Altman, 2012). However, correlation with MR-DTI findings in white matter 
changes with QRISK2 as well as the performance on neurocognitive assessments 
among healthy and asymptomatic individuals is still insufficient. Moreover, variation 
in MPs and its subpopulation counts in various diseases indicate their diagnostic 
importance, particularly in vascular pathologies. However, most of the previous MPs 
studies are skewed towards diseases populations and do not focus on healthy subjects 
with prevalence of WMHs. Hence, novel correlations of MPs and its subpopulation 
counts with an imaging modality, QRISK2 and neuropsychology profiles is need and 
can serve as potential surrogate markers for the onset and progression of the CSVD 
spectrum. 
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1.3 Objectives of The Study 
 
1.3.1 General objective 
 
To explore novel surrogate markers for the assessment of white matter integrity in 
cerebral small vessel disease (CSVD) among apparently healthy asymptomatic 
individuals with neuropsychological, neuroimaging and microparticles profiling. 
 
1.3.2 Specific objectives 
 
1. To determine the proportion of white matter hyperintensities (WMHs) among 
the study subjects 
2. To compare and correlate the QRISK2 cardiovascular risk prediction with 
longitudinal changes in white matter integrity among subjects with and without 
the WMHs. 
3. To compare and correlate the neuropsychological profiles with longitudinal 
changes in white matter integrity among subjects with and without the WMHs. 
4. To compare and correlate the microparticles (MPs) and its subpopulations’ 
profiles with longitudinal changes in white matter integrity among subjects 
with and without WMHs. 
5. To determine novel multimodal correlation of QRISK2, MPs subpopulations 
and neuropsychological profiles with neuroimaging parameters. 
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1.3.3 Research Questions 
 
1. Does QRISK2 cardio-cerebrovascular risk prediction differ with age and is it 
able to predict the integrity and health of white matter tracts? 
2.  Is there any relationship between QRISK2 cardio-cerebrovascular risk 
prediction with the prevalence of white matter hyperintensities (WMHs)? 
3. Does QRISK2 relate to the neuropsychological performance among healthy 
and asymptomatic individuals? 
4. Do the neuropsychological profiles among subjects with and without 
prevalence of WMHs significantly differ? 
5. Is the prevalence of WMHs affected by age? 
6. Does neuropsychological performance relate with white matter tracts’ 
integrity? 
7. Is there any correlation between QRISK2 and the level of circulating 
microparticles?  
8. Does MPs and its subpopulations correlate with the number and volume of 
WMHs lesions in healthy and symptomatic subjects? 
9. Does the level of circulating MPs influence a subject’s performance in 
cognitive and memories functions? 
10. Do changes in white matter integrity among healthy and asymptomatic subjects 
have to do with the level of circulating MPs? 
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1.3.4 Research hypothesis 
 
1. There is a significant correlation between QRISK2 with age and changes in 
white matter integrity.  
2. There is no significant relationship between cardiovascular risk prediction, 
level of circulating MPs with a subject’s neuropsychology performance. 
3. There is a significant association between the level of circulating MPs and 
QRISK2 
4. The level of certain MPs subpopulations can influence specific white matter 
tracts’ integrity. 
5. There is a significant relationship between white matter tracts’ integrity and 
QRISK2. 
6. There is a significant correlation between white matter integrity and a subject’s 
neuropsychology performance 
7. This study hypothesised that imaging changes of CSVD over time as delineated 
by DTI studies may serve as surrogate markers of CSVD together with 
potential novel correlations between a panel of MPs subpopulations, QRISK2 
and neuropsychological profiles among healthy and asymptomatic individuals. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Literature Search Strategy 
 
The search strategies for relevant literature employed the use of search engines and 
specific string of keywords within several electronic databases. The databases used 
included Google Scholar, Science Direct, PubMed, Wiley Online Library, and ISI Web 
of Knowledge. Only articles published in English were selected.  The literature search 
approach was divided into several parts. The first part included cerebral small vessel 
disease and silent stroke, using keywords: “cerebral small vessel disease AND silent 
stroke”. The seconds part concerned microparticles, using keywords: “circulating 
microparticles and strokes”, “cell-derived microparticles AND subpopulations”. The 
third focused upon cardiovascular risk in relation with cerebral small vessel disease 
and also cognitive function using keywords: “cardiovascular risk AND cerebral small 
vessel disease AND cognitive function”, “ischemic stroke AND cognitive”. Finally, 
further search focused upon supplementary research completion. 
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Part 1: Cerebral Small Vessel Disease (CSVD) 
 
2.2 Cerebral White Matter 
 
White matter is the term used to reflect glistening “white” fatty myelin sheath derived 
from oligodendrocytes that encircle many axons (Figure 2.1). Neuronal axons can be 
unmyelinated, lightly myelinated or heavily myelinated. Proportion of myelinated 
fibres (groups of axons) increases following phylogenetic, embryologic and 
developmental growth. The conduction capacity of axons differs according to 
unmyelinated slow-conducting and myelinated fast conducting (Wang et al., 2008).  
 
 
 
Figure 2.1: Schematic illustration of cerebral white matter. Left: diagrammatic 
representation of a neuron in which axon wrapped with oligodendrocytes forming 
myelin sheaths. Right: cerebral hemisphere, noted the different in white matter and 
grey matter. (image source for cerebral hemisphere adapted from: Baker & Haris, 
1892, retrieved from http://etc.usf.edu/clipart/8100/8166/human_brain_8166.htm). 
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There are three major cerebral white matter fibres: commissural, projection and 
association. The commissural fibres, connects the two cerebral hemispheres across the 
midline, hence regarded as bi-hemispheric fibres (Nieuwenhuys et al., 2008) (Figure 
2.2). There are two types of commissural fibres: homotopic and heterotopic fibres. The 
former connects corresponding region of two hemisphere. The latter connects one 
cortical area with non-corresponding areas of contralateral hemisphere. Examples of 
commissural fibres includes corpus callosum, anterior/posterior commissure and also 
hippocampal commissure (Standring et al., 2008).  
 
        
Figure 2.2: Schematic illustration of major types of commissural fibres (image source: 
https://neupsykey.com/cerebral-cortex-3/. Retrieved on 14th March 2018) 
 
 
In contrast, the projection fibres, interconnect and transmit impulses from 
cerebral cortex to spinal cord, brain stem and subcortical regions (Figure 2.3). Thus, 
frequently regarded as uni-hemispheric fibres. Major example of projection fibres 
includes corticospinal tracts (CST), thalamic radiations, optic radiations, and also 
fornix (Nieuwenhuys et al., 2008). Tracts are defined as groups of axons that have 
13 
 
similar corresponding functions. Radiations are defined as white matter fibres that 
fanned out together from or towards one target (Standring et al., 2008).  
 
 
 
Figure 2.3: Schematic illustration of major projections fibres (A-H) which interconnect 
cerebral cortex with other regions such as midbrain, subcortical regions and also spinal 
cord (Image source adapted from: Newell & Ernst, 1917, retrieved from 
http://etc.usf.edu/clipart/ 44000/44026/44026_cerebrum.htm on 14th March 2018) 
 
 
The next major white matter fibre is the association fibres which also known 
as uni-hemispheric fibres. These fibres interconnect multiple cerebral region in one 
particular hemisphere (Figure 2.4). Short U-fibres is the most prominent that 
interconnect adjacent gyri or long tracts that span the hemisphere (i.e. cingulum 
bundles, superior/inferior longitudinal fasciculus, arcuate fasciculus and also extreme 
capsule). Fasciculus is the term used for microscopically determinable fibres’ groups 
(Nieuwenhuys et al., 2008). Whilst, capsules are sheet of fibres that curved and 
partially surround the grey matter (Standring et al., 2008).  
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Figure 2.4: Schematic illustration of major association fibres, noted the superior 
longitudinal fasciculus and uncinate fasciculus (Image source adapted from: Sobatta, 
1907; retrieved from http://etc.usf.edu/clipart/36300/36301/brain_36301_lg.gif, on 
14th March 2018). 
 
 
Therefore, cerebral white matter consists of fibres pathways that transmit 
information in the form of impulses through link of interconnected axons from one 
cerebral cortical areas to another including subcortical areas that form neural circuits 
(Schmahmann et al., 2008). From total brain volume, 60% are represented by circuits 
of white matter tracts.  
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2.3 Cerebral Small Vessels (Blood Supply) 
 
The deep white matter, receives blood supply from the penetrating small vessel. The 
inner layer of these vessels is generally covered by endothelium monolayer with total 
area of 350m2 (in human) (Pries et al., 2000). The microvasculature health of the small 
vessel is maintained by normal functioning endothelial cells (Figure 2.5). 
 
 
Figure 2.5: Schematic illustration of blood vessels. Left: larger vessels (vein and 
artery), with multiple layer covering the vessels; Right: representation of small vessel, 
noted that it is surrounded by endothelial cells monolayer and associated with pericytes 
(image source adapted from: Cleaver & Melton, 2003). 
 
 
Current accepted definition of small vessels refers to all the vascular structures 
(small arteries, arterioles, capillaries, venules, and small veins) that are located in the 
brain parenchyma or in the subarachnoid space (Pantoni & Gorelick, 2014). Terminal 
arterioles including pial and medullary arterioles (4-5 cm long) are formed from 
cortical arteries that perpendicularly penetrate white matter (Martorella et al., 2012) 
(Figure 2.6). Branches of short cortical arteries (3-4 mm) also supply juxta-cortical 
white matter (U-fibres). Multiple anastomoses were established by cortical arteries 
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provide the cerebral cortex with rich arteriolar network. As the arteries penetrated deep 
into white matter they establish few more capillary anastomoses alongside pial 
arterioles forming relatively independent arteriolar metabolic units (Martorella et al., 
2012) (Figure 2.6). Apart from that, shorter deep sub-ependymal arteries that arise 
from choroid arteries also supply white matter. Moreover, basal ganglia are penetrated 
by another terminal branch of sub-ependymal arteries including thalamic and 
lenticulostriate perforating arteries originating from the larger vessel, middle cerebral 
artery (MCA). These penetrating arterioles are hardly anastomosed with each other 
thus parenchyma located at the adjacent of them are less vascularized.  This is in 
contrast to superficial penetrating arteries which are more vascularized.  
 
 
Figure 2.6: Schematic illustration of cerebral vasculature. Right: Different branches of 
cerebral arteries and their territories that supply cerebral white matter. Left: penetrating 
arteries and arterioles into deep white matter, from the image (1) represent cortical 
arteries (2) pial arterioles that supply deep white matter (2.1) short branches (3) 
anterior choroidal arteries that branch into sub-ependymal arteries (4) arterioles of sub-
ependymal (5) MCA branches into thalamic and lenticulostriate perforating arteries 
that supply basal ganglia (adapted from: Martorella et al., 2012). 
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2.4  CSVD: Definition and Pathophysiology  
 
One of the predominant types of strokes that resulted from occlusion (ischaemia) of 
small blood vessel deep within the brain is ischaemic stroke (Rouhl et al., 2009; Smith, 
2017). In ischemic or lacunar stroke, around up to 30% thought to be due to CSVD 
(Heye et al., 2015; Patel & Markus, 2011; Rouhl et al., 2009). 
 
It is generally accepted that small vessel disease (SVD) is a term used to 
describe the pathologic consequences of SVD on the brain parenchyma rather than the 
underlying diseases of the vessels (Wardlaw et al., 2013). Thus, the term CSVD is 
preferred to describe a brain injury that resides in poorly collateralized subcortical grey 
and deep white matter due to several of vasculo-pathologic processes that affect and 
cause occlusion to the perforating cerebral capillaries and arteries (mostly branches of  
MCA) that penetrate and supply the brain subcortical region (Benjamin et al., 2016; 
Hinman et al., 2015; Novakovic, 2010) (Figure 2.7).  
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Figure 2.7: Illustration of general aetiologies of CSVD. The picture shows branches of 
MCA that penetrates subcortical region of white matter and also grey matter. Embolus 
or thrombus may accumulate and cause occlusion (atheroma) upon parent MCA and 
penetrating arteriolar. The occlusion of perforating arteriolar can cause ischemia and 
eventually lacunar infarct may have formed. The core infarcts might affect surrounding 
tissue (penumbra). Diffused disruption of blood brain barrier following intrinsic 
CSVD also happened at arteriolar level indicating that certain plasma component 
invasion and deposited in vessel wall (adapted from: Shi & Wardlaw, 2016).  
 
 
 
Therefore, in general the term CSVD is used to describe a complex and 
heterogeneous disorder to indicate brain parenchymal injury associated with distal 
leptomeningeal and intracerebral vessel pathology (Ogata et al., 2014; de Bresser et 
al., 2018) through clinical, radiological, or pathological phenomena with various 
aetiologies that affect the pathologies of small arteries, arterioles, venules, and 
capillaries of the brain (Sorond et al., 2015; Yakushiji et al., 2018). 
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2.5 White Matter Hyperintensities (WMHs) 
 
The ischaemic consequences of several manifestation of CSVD such as WMHs, 
lacunar strokes, cerebral microbleeds, enlarged perivascular spaces, and small 
subcortical infarcts can be detected using MRI (Lambert et al., 2015; Sorond et al., 
2015; Yakushiji et al., 2016; Yakushiji et al., 2018). WMHs are commonly recognized 
as small ‘lacunes’ (Latin: for lake) in ageing brain or bright areas of small non-
cavitated high signal intensity on FLAIR and T2-weighted MRI parameters.  The 
lesion will increase with age because they evolve over a few months to years 
(Ovbiagele & Saver, 2006; Valdés Hernández et al., 2015; Wharton et al., 2015). 
Recognising the expanding CVSD manifestations from MRI imaging (symptomatic 
and asymptomatic), Wardlaw and colleagues proposed what is known as Standards for 
Reporting and Imaging of Small Vessel Disease (STRIVE) for the methods of visual 
identification and classification CSVD spectrum (Wardlaw et al., 2013) (Figure 2.8). 
 
In addition, WMHs are also regarded as an ischaemic white matter 
demyelination and can manifest as symptomatic or silent (asymptomatic) brain 
parenchyma lesion. Interestingly, this so-called ‘silent’ manifestation of CSVD is 
frequently reported as incidental finding from brain imaging of individuals who never 
experienced any symptom of stroke more frequently among the elderly (Valdés 
Hernández et al., 2015). It is also been proposed as a prognostic marker following a 
first symptomatic CSVD presentation, for instance acute lacunar stroke (van Norden 
et al., 2011).  
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Figure 2.8: STRIVE method of identification and classification of CSVD spectrum. 
Top: example of MRI images; Middle: schematic representation; Bottom: 
characteristic of changes related to CSVD (adapted from: Wardlaw et al., 2013). 
 
 
2.6 Aetiology and Consequences of WMHs   
 
About 95% of asymptomatic or SBI are lacunar infarcts (as seen as WMHs on MRI 
imaging) and are arguably more prevalent than symptomatic ones. The two major 
contributors to the progression of SBI include age and hypertension (Norrving, 2015). 
The key difference between SBI and symptomatic lacunar infarcts are their location 
and size. This is because both SBI and symptomatic lacunar infarcts have similar 
pathological appearance (Bailey et al., 2012). For example, most asymptomatic SBI 
are located within white matter periventricular space (periventricular lesion, PVL) and 
centrum semiovale (deep subcortical lesions, DSCL) (Kaiser et al., 2014; Wharton et 
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al., 2015), whereas, in symptomatic lacunar ischaemic stroke mostly affects the 
sensory and motor tracts (Valdés Hernández et al., 2015). 
 
However, the underlying pathomechanism of SBI or WMHs remains 
contentious, largely as a result of growing insights from histopathological, 
epidemiological, and physiological studies that contribute important information about 
it. In addition, healthy white matter is more myelinated than white matter of 
Alzheimer’s patients (Bartzokis et al., 2003) and has a high content of long chain fatty 
acids and less water content (by 12%) compared with grey matter. Previous study 
reported that WMHs are consistently related to age, hypertension and other 
cardiovascular risk factors (Prabakharan et al., 2012). Therefore, individual with 
extensive WMHs are at high risk for future stroke, i.e. WMHs serving as prognostic 
marker. Nevertheless, it is estimated that SBI or WMHs occur around 30% of healthy 
subjects over 60 years of age, and with a linear prevalence increment with age (de 
Leeuw et al., 2001).  
 
Reduced cerebral blood flow and focal neurologic signs are related to brain 
atrophy and have been found to correlate with number and volume of WMHs (Bahrani 
et al., 2017). Furthermore, WMHs are also associated with cognitive impairment, with 
the notion that a certain threshold must be achieved before this becomes clinically 
apparent (Debette & Markus, 2010). Alarmingly, WMHs have also been linked 
precursor of developing neuropsychiatric disorder such as schizophrenia (Berlow et 
al., 2010). 
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Part 2: Cerebrovascular Disease Risk and Risk Prediction 
 
2.7 Risk Factors for Cerebrovascular Disease 
 
In 1960, Framingham Heart Study was the first to recognised the non-modifiable and 
modifiable risk factors for cerebrovascular disease in the population setting (Mahmood 
et al., 2014). Understanding of such factors has helped facilitate the management and 
prevention of cardiovascular morbidities and mortality. Age, gender, race, ethnicity 
and heredity have been recognized as common non-modifiable risk factors for the 
onset and progression of stroke. Although these factors cannot be modified, they help 
identify those whose potentially at high risk, hence, enabling strategic management of 
modifiable risk factors such as smoking and cholesterol level.  
 
 In addition, age is the strongest determinant risk factor for stroke. It has been 
reported that, the risk for stroke for an individual is doubled at 10 successive years 
after 55 years of age, for both male and female (Smajlovic, 2015; Ovbiagele & 
Nguyen-Huynh, 2011). Furthermore, the incidence of stroke is 1.25 folds higher in 
male compared to female, as females tend to live longer than males (Morovic et al., 
2012). 
 
Stroke incidence and mortality are particularly varied among different race. 
Previous studies reported that, the incidence of stroke is double in black patients 
compared to white patients. For example, the incidence of stroke among black patient 
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is more than 2 folds higher than white, whilst Hispanic patients are 1.6 folds higher 
than white patients (Howard, 2013). Higher incidence of stroke also has been reported 
in Asians such as Chinese and Japanese (Ueshima et al., 2008).  
 
Moreover, the incidence and prevalence of stroke also elevated in individual 
with family history of stroke. The reasons for this are a genetic tendency for stroke, a 
genetic determination of other stroke risk factors, and a common familial exposure to 
environment or lifestyle risk. Previous studies suggested that, an increase risk for male 
whose mothers died from stroke and female who had a family history of stroke 
(Seshadari et al., 2010). In the Framingham Study and offspring analysis revealed that 
both paternal and maternal history of stroke conferred an increased risk of stroke 
(Romero & Wolf, 2013).  
 
2.8 Cardio-cerebrovascular Risk Prediction Assessment by QRISK2 
 
Currently, an online calculator has been established to predict the risk for cardio-
cerebrovascular disease within 10 years; such a tool includes QRISK 2 (Collins & 
Altman, 2010). QRISK2 is an online based risk prediction of cardio-cerebrovascular 
disease (http//:www.QRISK.org/index.php) (University of Nottingham and EMIS). It 
was developed in the United Kingdom (UK) based on information compiled between 
1993 and 2010 that contained the data for over 10 million patients registered with 550 
general practices in the UK. Hence, it is globally used and is annually updated.  
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QRISK2 is the updated version of QRISK1, whereby a new multivariable risk 
score that comprises all the risk factors in QRISK1 has been factored in, including 
self-assigned ethnicity and conditions associated with cardio-cerebrovascular risk 
including type 2 diabetes mellitus, hypertension, rheumatoid arthritis, renal disease 
and atrial fibrillation (Hippisley-Cox et al., 2008). Interactions between age and body 
mass index, systolic blood pressure, family history, smoking status, treated 
hypertension, diagnosed type 2 diabetes mellitus, and atrial fibrillation are also 
considered in QRISK2 (Table 2.1).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
